These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials. Chen Q, Lin MH, Chen ML, Liu ZY, Chai D, Wang R. Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571 [Abstract] [Full Text] [Related]
25. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885 [Abstract] [Full Text] [Related]
32. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Saliba F, Pascher A, Cointault O, Laterre PF, Cervera C, De Waele JJ, Cillo U, Langer RM, Lugano M, Göran-Ericzon B, Phillips S, Tweddle L, Karas A, Brown M, Fischer L, TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) Investigators, TENPIN Liver Transplant European Study Into the Prevention of Fungal Infection Investigators. Clin Infect Dis; 2015 Apr 01; 60(7):997-1006. PubMed ID: 25520332 [Abstract] [Full Text] [Related]
33. Safety and efficacy of micafungin for prophylaxis against invasive fungal infections in Japanese patients undergoing hematopoietic stem cell transplantation: Results of a post-marketing surveillance study. Kobayashi C, Hanadate T, Niwa T, Hirano Y, Yoshiyasu T, So M, Matsui K. J Infect Chemother; 2015 Jun 01; 21(6):438-43. PubMed ID: 25749360 [Abstract] [Full Text] [Related]